Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (January 2023)
21 slides from Sutro Biopharma's investor presentation, Jan 9, 2023
Slide 1: Company Overview
Company Overview January 9, 2023 Sutro Biopharma NASDAQ: STRO Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: Six Product Candidates in Clinical Development are Enabled by Sutro's Platform
Modality Program Target(s) Indication Discovery Preclinical Phase 1/1b Phase 2/3 Partner Antibody-Drug Conjugate (ADC) Luvelta (STRO-002) FolRα Ovarian Cancer Ovarian Cancer (bevacizumab combo) Endometrial Cancer NSCLC/Non-Gyn Cancers STRO-001 CD74 Lymphoma Multiple Myeloma CC-99712 BCMA Multiple My
Slide 4: Upcoming milestones and key objectives
Data on Phase 1 dose-expansion and regulatory path forward for the development of luvelta Initiate registration-directed Phase 2/3 trial, REFRaME, in platinum-resistant ovarian cancer (2Q 2023) Provide regulatory update and clinical development plan for infants and children with relapsed/refractory
Slide 5: Luveltamab Tazevibulin (Luvelta, STRO-002)
Luveltamab Tazevibulin (Luvelta, STRO-002)
Slide 6: Advanced Ovarian Cancer Has a High Unmet Medical Need
Advanced Ovarian Cancer Has a High Unmet Medical Need Ovarian cancer is the most common cause of death from gynecological cancers Accounts for 2.1% of all estimated cancer deaths(1,2) Almost half of affected women live less than five years following diagnosis1,2 In 2022, an estimated 19,880 new ovar
Slide 7: Two-Part Phase 1 Study for Patients with Advanced Ovarian Cancer
Two-Part Phase 1 Study for Patients with Advanced Ovarian Cancer(1) Explored dosing regimen and biomarker levels for which luvelta is optimal 1. Phase 1 for patients with advanced ovarian cancer is named STRO-001-GM1, clinicaltrials.gov NCT identifier: NCT03748186. 2. Three patients were not evaluab
Slide 8: Luvelta Phase 1 Data Establishes FolRα-Selection Criteria
RECIST-Evaluable Patients N=41 N=32 N=9 N=12 N=20 N=16 N=16 PR 13 12 1 4 8 5 7 ORR (95%, CI), % 31.7 (18.1, 48.1) 37.5 (21.1, 56.3) 11.1 (0.3, 48.3) 33.3 (10.0, 65.1) 40.0 (19.1, 63.9) 31.3 (11.0, 58.7) 43.8 (19.8, 70.1) Median DOR (95% CI), mo 5.4 (2.9, 11.0) 5.5 (2.5, 11.0) 2.9 5.6 (2.5, NE) 5.5 (
Slide 9: Majority of FolRα-Selected Patients Experienced Disease Control
Majority of FolRα-Selected Patients Experienced Disease Control 12 FolRα-selected patients demonstrated confirmed partial response Note: Data are as of November 8, 2022. 1. Data on FolRα-selected patients who are evaluable for RECIST v1.1. 2. Disease control includes SD ≥ 6 weeks. BOR, best overall
Slide 10: Patients Had Durable Responses even with Dose Modifications
Patients Had Durable Responses even with Dose Modifications Patients who started at the higher dose experienced rapid time to response Note: Data are as of November 8, 2022. 1. Data are from Cohort A of Phase 1 dose expansion on FolRα-selected patients who are evaluable for RECIST v1.1. 2. Patients
Slide 11: Cohort C as a Deep Dive Into Managing Neutropenia
Cohort C as a Deep Dive Into Managing Neutropenia Prophylactic use of pegfilgrastim reduced Grade 3+ neutropenia and dose delays Grade 3+ Neutropenia at Cycle 1 P=0.006 85.0% less grade 3+ neutropenia at cycle 1 Dose Delays at Cycle 2 P=0.021 60.6% less dose delay at cycle 2 Part 2 Dose-expansion co
Slide 12: Most Common Treatment-Emergent Adverse Event was Neutropenia
Most Common Treatment-Emergent Adverse Event was Neutropenia Most Common Grade 3+ TEAEs (≥2 Subjects) by Dose and General Category No new safety signals were observed, including the absence of meaningful drug-related ocular and lung AEs Note: Data are as of November 8, 2022 on all patients enrolled
Slide 13: Luvelta Has a Favorable Product Target Profile
Luvelta (STRO-002) Has a Favorable Product Target Profile Confidence to move forward into registrational-enabling study Note: Cohort A data are as of November 8, 2022. Cohort C data are as of December 8, 2022. Potential to treat ~80% of patients with platinum-resistant ovarian cancer Efficacy demons
Slide 14: Integrated Strategy for Phase 2/3 Study, REFRaME
Luvelta Clinical Integrated Strategy for Phase 2/3 Study, REFRaME Integrated design to potentially support accelerated and full approvals in platinum-resistant ovarian cancer Part 1: Lead-In Dose Selection Key eligibility criteria Platinum resistant ovarian cancer, prior bevacizumab required 1–3 pri
Slide 15: Luvelta development plan across indications
Monotherapy Platinum-resistant ovarian cancer Phase 2/3 Market size: ~4K patients per year in the U.S. (FolRα-selected) Endometrial cancer Phase 1 expansion Incidence: Across all stages, not FolRα-selected, ~66K newly diagnosed/year Pediatric RAM phenotype AML with CBF/GLIS2 mutation Compassionate u
Slide 16: STRO-003 and Emerging Research Portfolio
STRO-003 and Emerging Research Portfolio
Slide 17: STRO-003 is a single homogeneous ADC with DAR 8, targeting ROR1
STRO-003 is a single homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 8, targeting ROR1 tumor antigen 1 2 3 4 pAMF ROR1 Targeted ROR1 epitope is overexpressed in diverse cancers including hematological and solid tumor indications Precisely positioned non-natural amino ac
Slide 18: Drug Discovery Platform Enables Best-in-Class or First-in-Class Molecules
Enhanced tumor targeting of cytotoxic payloads e.g. M1231 Bispecific ADC ADC: targeting novel payloads Tumor Antigen Dual Tumor Antigens Conjugated Antibody Tumor Antigen Modality Drug Properties Target Structure Tumor Associated Antigen Targets ROR1 Tissue Factor PTK7 Integrin B6 Liv-1 CEACAM5 Tool
Slide 19: Strategic iADC Collaboration with Astellas
$90M upfront to develop iADCs for up to three targets $422.5M in development, regulatory and commercial milestones for each product candidate, plus tiered royalties ranging from low-double digit to mid-teen percentages Builds on success of Sutro’s ADC platform and engineering expertise Leverages Ast
Slide 20: Financial Overview
$287.3M(1) in cash, cash equivalents & marketable securities as of September 30, 2022 Projected cash runway into 1H 2024(1), based on current business plans and assumptions ~1.5M shares of Vaxcyte (Nasdaq: PCVX) not included in the above reported cash, as of September 30, 2022(2) Funding generated f
Slide 21: Experienced Leadership Team
Experienced Leadership Team William Newell, JD Chief Executive Officer and Member of the Board of Directors Trevor Hallam, PhD President of Research and Chief Scientific Officer Ed Albini, MBA Chief Financial Officer Shabbir Anik, PhD Chief Technical Operations Officer Linda Fitzpatrick Chief People
Sutro Biopharma — Investor Presentation (January 2023) on 6ix